CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

Context

This dataset provides State-by-state data on United States COVID-19 vaccinations between 20 December of 2020 and 12 January of 2022. Data is taken daily by the United States Centers for Disease Control and Prevention

Columns

us_vaccinations File

- location: State name.

- date: date of the case.

- total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again.

- total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the state.

- daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead.

- daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here.

- daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the state.

- people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

- people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the state.

- people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

- people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the state.

- total_distributed: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System.

- total_distributed_per_hundred: cumulative counts of COVID-19 vaccine doses recorded as shipped in CDC's Vaccine Tracking System per 100 people in the total population of the state.

- share_doses_used: share of vaccination doses administered among those recorded as shipped in CDC's Vaccine Tracking System.

Data as of: May 18, 2021

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-ZIP-Code/2ani-ic5x.

NOTE, 3/30/2023: We have added columns for bivalent (updated) doses to this dataset. We have also added age group columns for 0-17 and 18-64 and stopped updating the 5+ and 12+ columns, although previously published values remain for those columns.

COVID-19 vaccinations administered to Chicago residents based on the home ZIP Code of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). The ZIP Code where a person lives is not necessarily the same ZIP Code where the vaccine was administered.

Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine.

·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received.

·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains.

·Total doses administered: Number of all COVID-19 vaccine doses administered.

Data Notes: Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, and number of people who have received a bivalent dose. Cumulative totals for each measure as of that date are also provided. Vaccinations are counted based on the day the vaccine was administered.

Coverage percentages are calculated based on cumulative number of people who have received at least one vaccine dose, cumulative number of people who have a completed vaccine series, and cumulative number of people who have received a bivalent dose in each ZIP Code.

Population counts are from the U.S. Census Bureau American Community Survey 2015-2019 5-year estimates and can be seen in the ZIP Code, 2019 rows of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa).

Actual counts may exceed population estimates and lead to >100% coverage, especially in areas with small population sizes. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination which may lead to over or under estimates of vaccination coverage by geography. 

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec.

COVID-19 vaccinations administered to Chicago residents based on home address, as reported by medical providers in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). I-CARE includes doses administered in Illinois and some doses administered outside of Illinois and reported in I-CARE by Illinois providers.

Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine.

·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received.

·People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19.

·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains.

·Total doses administered: Number of all COVID-19 vaccine doses administered.

Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, number of people with a monovalent booster dose, and number of people with a bivalent dose. Cumulative totals are also provided for each measure as of that date. Vaccinations are counted based on the day the vaccine was administered.

Coverage percentages for the City of Chicago are calculated based on cumulative number of people with that vaccination status.

Daily totals of all doses, number of people with at least one vaccine dose, number of people who have completed a vaccine series, number of people with a booster dose, and number of people with a bivalent dose are shown by age group, gender, and race/ethnicity.

Denominators are from the U.S. Census Bureau American Community Survey 1-year estimate for 2019 and can be seen in the Citywide, 2019 row of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa).

The Chicago Department of Health (CDPH) uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense, are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that can be linked to their record, such as someone receiving a vaccine dose in another state, the number of people with a completed series or a booster dose is underestimated. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate first dose records for a person and overestimate of the number of people with at least one dose and underestimate the number of people with a completed series or booster dose.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete

On 6/28/2023, data on cases by vaccination status will be archived and will no longer update.

A. SUMMARY This dataset represents San Francisco COVID-19 positive confirmed cases by vaccination status over time, starting January 1, 2021. Cases are included on the date the positive test was collected (the specimen collection date). Cases are counted in three categories: (1) all cases; (2) unvaccinated cases; and (3) completed primary series cases.

1. All cases: Includes cases among all San Francisco residents regardless of vaccination status.

2. Unvaccinated cases: Cases are considered unvaccinated if their positive COVID-19 test was before receiving any vaccine. Cases that are not matched to a COVID-19 vaccination record are considered unvaccinated.

3. Completed primary series cases: Cases are considered completed primary series if their positive COVID-19 test was 14 days or more after they received their 2nd dose in a 2-dose COVID-19 series or the single dose of a 1-dose vaccine. These are also called “breakthrough cases.”

On September 12, 2021, a new case definition of COVID-19 was introduced that includes criteria for enumerating new infections after previous probable or confirmed infections (also known as reinfections). A reinfection is defined as a confirmed positive PCR lab test more than 90 days after a positive PCR or antigen test. The first reinfection case was identified on December 7, 2021.

Data is lagged by eight days, meaning the most recent specimen collection date included is eight days prior to today. All data updates daily as more information becomes available.

B. HOW THE DATASET IS CREATED Case information is based on confirmed positive laboratory tests reported to the City. The City then completes quality assurance and other data verification processes. Vaccination data comes from the California Immunization Registry (CAIR2). The California Department of Public Health runs CAIR2. Individual-level case and vaccination data are matched to identify cases by vaccination status in this dataset. Case records are matched to vaccine records using first name, last name, date of birth, phone number, and email address.

We include vaccination records from all nine Bay Area counties in order to improve matching rates. This allows us to identify breakthrough cases among people who moved to the City from other Bay Area counties after completing their vaccine series. Only cases among San Francisco residents are included.

C. UPDATE PROCESS Updates automatically at 08:00 AM Pacific Time each day.

D. HOW TO USE THIS DATASET Total San Francisco population estimates can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS). To identify total San Francisco population estimates, filter the view on “demographic_category_label” = “all ages”.

Population estimates by vaccination status are derived from our publicly reported vaccination counts, which can be found at COVID-19 Vaccinations Given to SF Residents Over Time.

The dataset includes new cases, 7-day average new cases, new case rates, 7-day average new case rates, percent of total cases, and 7-day average percent of total cases for each vaccination category.

New cases are the count of cases where the positive tests were collected on that specific specimen collection date. The 7-day rolling average shows the trend in new cases. The rolling average is calculated by averaging the new cases for a particular day with the prior 6 days.

New case rates are the count of new cases per 100,000 residents in each vaccination status group. The 7-day rolling average shows the trend in case rates. The rolling average is calculated by averaging the case rate for a part

Analysis of ‘COVID-19 Vaccinations by ZIP Code’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/73e760fb-93e8-49cb-8d11-3e81c4e41c82 on 13 February 2022.

--- Dataset description provided by original source is as follows ---

NOTE, 11/4/2021: With the authorization of vaccine for children age 5-11, we have added three columns to this dataset. For each grouping of columns (Total, 1st Dose, and Series Completed), there is now a 5+ column. Care should be taken when summing values to avoid accidental double-counting.

COVID-19 vaccinations administered to Chicago residents based on the home ZIP Code of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). The ZIP Code where a person lives is not necessarily the same ZIP Code where the vaccine was administered.

Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a COVID- 19 vaccine series. Requirements vary depending on the vaccine received. Pfizer and Moderna vaccines require two doses for a completed series. Johnson & Johnson is a single-dose vaccine. ·Total doses administered: Number of all COVID-19 vaccine doses administered.

Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, and number of people who have a completed vaccine series. Cumulative totals for each measure as of that date are also provided. Vaccinations are counted based on the day the vaccine was administered.

Coverage percentages are calculated based on cumulative number of people who have received at least one vaccine dose and cumulative number of people who have a completed vaccine series in each ZIP Code.

Population counts are from the U.S. Census Bureau American Community Survey 2015-2019 5-year estimates and can be seen in the ZIP Code, 2019 rows of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa).

Actual counts may exceed population estimates and lead to >100% coverage, especially in areas with small population sizes. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination which may lead to over or under estimates of vaccination coverage by geography. 

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

--- Original source retains full ownership of the source dataset ---

On 6/28/2023, data on cases by vaccination status will be archived and will no longer update. A. SUMMARY This dataset represents San Francisco COVID-19 positive confirmed cases by vaccination status over time, starting January 1, 2021. Cases are included on the date the positive test was collected (the specimen collection date). Cases are counted in three categories: (1) all cases; (2) unvaccinated cases; and (3) completed primary series cases. All cases: Includes cases among all San Francisco residents regardless of vaccination status. Unvaccinated cases: Cases are considered unvaccinated if their positive COVID-19 test was before receiving any vaccine. Cases that are not matched to a COVID-19 vaccination record are considered unvaccinated. Completed primary series cases: Cases are considered completed primary series if their positive COVID-19 test was 14 days or more after they received their 2nd dose in a 2-dose COVID-19 series or the single dose of a 1-dose vaccine. These are also called “breakthrough cases.” On September 12, 2021, a new case definition of COVID-19 was introduced that includes criteria for enumerating new infections after previous probable or confirmed infections (also known as reinfections). A reinfection is defined as a confirmed positive PCR lab test more than 90 days after a positive PCR or antigen test. The first reinfection case was identified on December 7, 2021. Data is lagged by eight days, meaning the most recent specimen collection date included is eight days prior to today. All data updates daily as more information becomes available. B. HOW THE DATASET IS CREATED Case information is based on confirmed positive laboratory tests reported to the City. The City then completes quality assurance and other data verification processes. Vaccination data comes from the California Immunization Registry (CAIR2). The California Department of Public Health runs CAIR2. Individual-level case and vaccination data are matched to identify cases by vaccination status in this dataset. Case records are matched to vaccine records using first name, last name, date of birth, phone number, and email address. We include vaccination records from all nine Bay Area counties in order to improve matching rates. This allows us to identify breakthrough cases among people who moved to the City from other Bay Area counties after completing their vaccine series. Only cases among San Francisco residents are included. C. UPDATE PROCESS Updates automatically at 08:00 AM Pacific Time each day. D. HOW TO USE THIS DATASET Total San Francisco population estimates can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS). To identify total San Francisco population estimates, filter the view on “demographic_category_label” = “all ages”. Population estimates by vaccination status are derived from our publicly reported vaccination counts, which can be found at COVID-19 Vaccinations Given to SF Residents Over Time. The dataset includes new cases, 7-day average new cases, new case rates, 7-day average new case rates, percent of total cases, and 7-day average percent of total cases for each vaccination category. New cases are the count of cases where the positive tests were collected on that specific specimen collection date. The 7-day rolling average shows the trend in new cases. The rolling average is calculated by averaging the new cases for a particular day with the prior 6 days. New case rates are the count of new cases per 100,000 residents in each vaccination status group. The 7-day rolling average shows the trend in case rates. The rolling average is calculated by averaging the case rate for a part

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

This archived public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties.

The COVID-19 community levels were developed using a combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days. The COVID-19 community level was determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge.

Using these data, the COVID-19 community level was classified as low, medium, or high.

COVID-19 Community Levels were used to help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

Archived Data Notes:

This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022.

March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released.

March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate.

March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset.

March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases.

March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average).

March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior.

April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

April 21, 2022: COVID-19 Community Level (CCL) data released for counties in Nebraska for the week of April 21, 2022 have 3 counties identified in the high category and 37 in the medium category. CDC has been working with state officials t

As of March 20, 2023, over 13 billion COVID-19 vaccine doses had been administered worldwide, with the United States accounting for almost 672 million of this total. This statistic shows the number of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

The United States COVID-19 Trends and Impact Survey (CTIS) was a voluntary survey of Facebook users in the United States conducted from April 2020 to June 2022. CTIS was intended to aid in pandemic forecasting and response at fine spatiotemporal detail. Through collaboration with Meta, it randomly sampled Facebook active users at a rate sufficient to provide roughly 35,000 responses per day, on average. Survey questions covered topics including COVID-like symptoms, behavior (such as social distancing), COVID testing, mental health, health-related beliefs, trust in officials and information sources, schooling, vaccination acceptance and hesitancy, and related subjects. Respondents provided their ZIP code. Demographic variables include age, gender, education, race/ethnicity, and occupation. Meta generated survey weights to correct for non-response and to match the US adult population age and gender distribution. The 27 datasets make up the microdata. Users should see the Microdata User Guide for documentation on the use and interpretation of the microdata files. Two zip files are available for public download: a monthly data zip file and a weekly data zip file. These include the aggregate data. To access these files, go to the "Download" tab and select "Other." Ensure you have enough storage space before proceeding, as the files are large.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased its collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit: U.S. Centers for Disease Control and Prevention (CDC)For more information, visit the Johns Hopkins Coronavirus Resource Center.This map is updated weekly and currently shows data through March 5, 2023, which will be the final update of this map.Note: Nebraska stopped reporting county level-results on 5/25/2021 and re-started on 9/26/21 with a lump-sum representing the previous four months - this impacted the weekly sum of cases fields.It shows COVID-19 Trend for the most recent Monday with a colored dot for each county. The larger the dot, the longer the county has had this trend. Includes Puerto Rico, Guam, Northern Marianas, U.S. Virgin Islands.The intent of this map is to give more context than just the current day of new data because daily data for COVID-19 cases is volatile and can be unreliable on the day it is first reported. Weekly summaries in the counts of new cases smooth out this volatility. Click or tap on a county to see a history of trend changes and a weekly graph of new cases going back to February 8, 2020. This map is updated every Monday* based on data through the previous Sunday. See also this version of the map for another perspective.COVID-19 Trends show how each county is doing and are updated daily. We base the trend assignment on the number of new cases in the past two weeks and the number of active cases per 100,000 people. To learn the details for how trends are assigned, see the full methodology. There are five trends:Emergent - New cases for the first time or in counties that have had zero new cases for 60 or more days.Spreading - Low to moderate rates of new cases each day. Likely controlled by local policies and individuals taking measures such as wearing masks and curtailing unnecessary activities.Epidemic - Accelerating and uncontrolled rates of new cases.Controlled - Very low rates of new cases.End Stage - One or fewer new cases every 5 days in larger populations and fewer in rural areas.*Starting 8/22/2021 we began updating on Mondays instead of Tuesdays as a result of optimizing the scripts that produce the weekly analysis. For more information about COVID-19 trends, see the full methodology. Data Source: Johns Hopkins University CSSE US Cases by County dashboard and USAFacts for Utah County level Data.

The global rabies vaccine market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.10% from 2025 to 2033. This expansion is driven by several key factors. Increasing global animal populations, particularly in developing nations, necessitate wider vaccination programs to prevent rabies transmission to humans. Furthermore, rising awareness of rabies prevention, coupled with improved healthcare infrastructure in some regions, is bolstering demand for both pre-exposure (PEV) and post-exposure prophylaxis (PEP) vaccines. The market is segmented by product type (Baby Hamster Kidney (BHK), Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and others), vaccination type (PEV and PEP), and end-user (animals and humans). The human segment is expected to experience significant growth due to increased vaccination campaigns targeting high-risk populations like veterinarians and wildlife handlers. Technological advancements in vaccine production, leading to more effective and safer vaccines, also contribute to market growth. However, the market faces certain challenges, including the high cost of vaccines, particularly in low-income countries, and the logistical hurdles associated with vaccine distribution in remote areas. Despite these constraints, the continued threat of rabies and the ongoing efforts to eradicate the disease globally promise sustained growth for the rabies vaccine market in the coming years. The competitive landscape comprises both large multinational pharmaceutical companies like GlaxoSmithKline, Merck & Co., and Sanofi, and smaller specialized players like Berna Biotech. These companies are engaged in research and development to enhance vaccine efficacy and safety, further driving market growth. The geographical distribution of the market reveals strong performance in North America and Europe due to established healthcare infrastructure and high awareness. However, the Asia-Pacific region, driven by significant animal populations and rising disposable incomes, is anticipated to witness substantial growth in the forecast period. Emerging markets in Africa and South America present significant opportunities for market expansion, although challenges related to infrastructure and affordability need to be addressed. The market's future trajectory hinges on sustained investment in public health initiatives, continued research into advanced vaccine technologies, and effective strategies to improve access to rabies vaccines in underserved regions. Strategic partnerships between governments, healthcare organizations, and pharmaceutical companies will play a crucial role in achieving global rabies eradication and thus boosting market growth further. Recent developments include: In April 2022, Cadila Pharmaceuticals launched a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This is a three-dose regimen to be given over a period of one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses., In August 2020, Bavarian Nordic A/S announced that it was starting commercial operations in the United States for Rabipur/RabAvert (Rabies Vaccine) and Encepur (Tick-Borne Encephalitis Vaccine) after acquiring them from GlaxoSmithKline plc (GSK).. Key drivers for this market are: Growing Burden of Mortality due to Rabies, Large Population of Stray Dogs in Low and Middle Income Countries; Growing Pet Management technological Advancements and Services. Potential restraints include: Growing Burden of Mortality due to Rabies, Large Population of Stray Dogs in Low and Middle Income Countries; Growing Pet Management technological Advancements and Services. Notable trends are: The Purified Chick Embryo Cell Rabies Vaccine is Expected to Witness Growth Over the Forecast Period.

This public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties. This dataset contains the same values used to display information available on the COVID Data Tracker at: https://covid.cdc.gov/covid-data-tracker/#county-view?list_select_state=all_states&list_select_county=all_counties&data-type=CommunityLevels The data are updated weekly.

CDC looks at the combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days — to determine the COVID-19 community level. The COVID-19 community level is determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge. Using these data, the COVID-19 community level is classified as low, medium, or high. COVID-19 Community Levels can help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

See https://www.cdc.gov/coronavirus/2019-ncov/science/community-levels.html for more information.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

For more details on the Minnesota Department of Health COVID-19 thresholds, see COVID-19 Public Health Risk Measures: Data Notes (Updated 4/13/22). https://mn.gov/covid19/assets/phri_tcm1148-434773.pdf

Note: This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022. March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released. March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate. March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset. March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases. March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average). March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior. April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

This data collection provides information on labor force activity for the week prior to the survey. Comprehensive data are available on the employment status, occupation, and industry of persons 14 years old and over. Also shown are personal characteristics such as age, sex, race, marital status, veteran status, household relationships, educational background, and Spanish origin. Supplemental data provide information on disease history and/or protection through immunization against the common childhood diseases (diphtheria, tetanus, and whooping cough, polio, measles, rubella, chicken pox, and mumps) for persons 0-19 years of age. Data on immunization against influenza and pneumonia are available for all persons. Data are also available for adults on diabetes, chronic kidney disease, and certain chronic heart and lung conditions. Also provided is an indicator for children 0-5 years of age who were enrolled in licensed day care centers during the past year. For persons 16 years old and older who had smoked a minimum of 100 cigarettes, the following data are provided: age first started smoking, if they currently smoke, and whether other tobacco products such as snuff, chewing tobacco, cigars, and pipe tobacco were used. (Source: downloaded from ICPSR 7/13/10)

Please Note: This dataset is part of the historical CISER Data Archive Collection and is also available at ICPSR at https://doi.org/10.3886/ICPSR09133.v1. We highly recommend using the ICPSR version as they may make this dataset available in multiple data formats in the future.

As of March 16, 2022, there was a total of approximately 5.9 million confirmed cases of coronavirus disease (COVID-19) in Japan, with around 529 thousand people needing inpatient treatment.

Development of cases in Japan Generally, the increase of new COVID-19 cases recorded from January to March 2020 in Japan followed a slower trajectory as compared to, for example, China, Europe, or the United States of America. The first reported case of COVID-19 in Japan was confirmed on January 16, 2020, when a man that had returned from Wuhan city, China, was tested positive. The first transmission within Japan was recorded on January 28. The number of new cases then increased tenfold in February. April saw a further acceleration of the infection rate. Consequently, the Japanese government declared a nationwide state of emergency that month. The government announced a state of emergency for the second time in January 2021, the third time in April 2021, and the forth time in the July 2021.

Vaccine rollout The Japanese government started the distribution of COVID-19 vaccination in February 2021, mainly for medical professionals. The administration of vaccination for general citizens commenced in April for senior citizens. The vaccine rate of the population was just over 74.7 percent for second doses as of March 2022.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figure page. 

As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.

The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.

Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.

Microneutralization immune responses (MN50) for NVX-CoV2373 study treatments by study group and age subgroup (18 to 59 years and 60 to 84 years).

Data includes COVID-19 case trends by county, age, new cases by date, case rates by county (including recoveries and deaths), COVID-19 data by race, and COVID-19 Maine cases vs other states. The website contains also information about hospitalization, contact tracing, testing, cases demographics, vaccination, cases by ZIP and COVID variants. The data is compiled by Maine CDC and events are reported according to the day they happened. Data is open access and available to the public.